Basel, 30. Juni 2017
Reminder: Roche Analyst Event at ISTH 2017
Monday, 10 July 2017, 6:30pm CEST
We kindly invite investors and analysts to participate in an analyst briefing during the International Society on Thrombosis and Hemostasis Congress (ISTH) in Berlin 8 – 13 July 2017.
During the briefing, Roche will discuss new data for emicizumab (ACE910) in hemophilia A:
HAVEN1 - phase 3 study of emicizumab (ACE910) prophylaxis in persons with hemophilia A with inhibitors
HAVEN2 - phase 3 study of emicizumab (ACE910) in pediatric persons with hemophilia A with inhibitors
Monday, 10 July 2017
6:00pm Registration desk opens
6:30pm Start of meeting
7:45pm End of meeting followed by a buffet reception
Hotel Berlin, Berlin
HAVEN1: Ph3 data of emicizumab (ACE910) prophylaxis in adults with hemophilia A with inhibitors
Prof. Dr. med. Johannes Oldenburg, University Clinic Bonn, Institute of Experimental Hematology and Transfusion Medicine
HAVEN2: Ph3 interim data of emicizumab (ACE910) prophylaxis in pediatrics with hemophilia A with inhibitors; aspects of disease management
Gallia Levy, M.D., Medical Director Hematology
Emicizumab global development program
Cristin Hubbard, Lifecycle Leader emicizumab
Daniel O’Day, CEO Roche Pharmaceuticals
To register for the event, please follow the link (Password: Analyst2017).
Dial in to the conference 10-15 minutes prior to the scheduled start, using the following dial-in numbers (listen-only mode, no live-access to speakers):
+41 (0) 58 310 5000 (Europe and ROW) or
+44 (0) 203 059 5862 (UK) or
+1 (1) 631 570 5613 (USA)
Alternatively a live audio webcast can be accessed via http://ir.roche.com. The presentation slides will be available from the IR website at http://ir.roche.com following to the closure of the ISTH meeting.
A replay of the webcast will be available on demand on the Roche website.
Head of Investor Relations
Investor Relations Officer